Antisense oligonucleotides as therapeutics for hyperlipidaemias
作者： Rosanne M Crooke
关键词:
摘要: Hyperlipidaemia, due to elevations of low-density lipoprotein cholesterol (LDL-C) or triglycerides (TGs), is recognised as a significant risk factor contributing the development coronary heart disease (CHD), leading cause morbidity and mortality in Western world. Even though variety established antihyperlipidaemic agents are available, majority high-risk patients do not reach their lipid goals, indicating need for new more effective therapeutics be used alone combination with existing drugs. Antisense oligonucleotides (ASOs), designed specifically selectively inhibit novel targets involved cholesterol/TG homeostasis, represent class that may prove beneficial treatment hyperlipidaemias resulting from various genetic, metabolic behavioural factors. This article describes antisense technology platform, highlights advantages these drugs hyperlipidaemia reviews current research this area.
informahealthcare.com参考文章(104)
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels The New England Journal of Medicine. ,vol. 339, pp. 1349- 1357 ,(1998) , 10.1056/NEJM199811053391902
S P Henry, A A Levin, R S Geary, R Yu, Drug properties of second-generation antisense oligonucleotides: how do they measure up to their predecessors? Current opinion in investigational drugs. ,vol. 2, pp. 1444- 1449 ,(2001)
H K Das, T Leff, J L Breslow, Cell type-specific expression of the human apoB gene is controlled by two cis-acting regulatory regions. Journal of Biological Chemistry. ,vol. 263, pp. 11452- 11458 ,(1988) , 10.1016/S0021-9258(18)37978-X
Rai Ajit K. Srivastava, L. Toth, Neelam Srivastava, Myron E. Hinsdale, Nobuyo Maeda, A.B. Cefalu´, Maurizio Averna, Gustav Schonfeld, Regulation of the apolipoprotein B in heterozygous hypobetalipoproteinemic knock-out mice expressing truncated apoB, B81. Low production and enhanced clearance of apoB cause low levels of apoB Molecular and Cellular Biochemistry. ,vol. 202, pp. 37- 46 ,(1999) , 10.1023/A:1007030531478
Salim Yusuf, MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary The Lancet. ,vol. 360, pp. 7- 22 ,(2002)
WAYNE M. GALBRAITH, WILLIAM C. HOBSON, PATRICIA C. GICLAS, PAUL J. SCHECHTER, SUDHIR AGRAWAL, Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense research and development. ,vol. 4, pp. 201- 206 ,(1994) , 10.1089/ARD.1994.4.201
Robert H. Knopp, Drug treatment of lipid disorders The New England Journal of Medicine. ,vol. 341, pp. 498- 511 ,(1999) , 10.1056/NEJM199908123410707
Anne Minnich, Nian Tian, Lisa Byan, Glenda Bilder, A potent PPARα agonist stimulates mitochondrial fatty acid β-oxidation in liver and skeletal muscle American Journal of Physiology-endocrinology and Metabolism. ,vol. 280, ,(2001) , 10.1152/AJPENDO.2001.280.2.E270
Nobuyo Maeda, Jesús Osada, Hao Li, Denise Lee, Paula Oliver, Steven H. Quarfordt, Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia. Journal of Biological Chemistry. ,vol. 269, pp. 23610- 23616 ,(1994) , 10.1016/S0021-9258(17)31559-4
Hui Zhi Lin, Shi Qi Yang, Christine Chuckaree, Francis Kuhajda, Gabriele Ronnet, Anna Mae Diehl, Metformin reverses fatty liver disease in obese, leptin-deficient mice Nature Medicine. ,vol. 6, pp. 998- 1003 ,(2000) , 10.1038/79697